Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy
Status:
Completed
Trial end date:
2020-03-06
Target enrollment:
Participant gender:
Summary
To demonstrate the efficacy of ranolazine in improving coronary microvascular and diastolic
dysfunction in patients affected by HCM evaluating changes in maximum (i.e. during
dipyridamole-induced coronary vasodilatation) myocardial blood flow (MBF) measured by PET at
baseline and after 4 months of treatment with ranolazine in patients with non obstructive
HCM.